Efficacy and safety of semaglutide in non-diabetic adults with overweight or obesity: A meta-analysis of randomized controlled trials
European Journal of Pharmacology · 2026-02 · 1015 · 178587
DOI: 10.1016/j.ejphar.2026.178587 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Pharmacology, 2026-02. Verfasst von Shenyue Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Overweight, Anti-Obesity Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Semaglutide has demonstrated significant weight loss benefits, but comprehensive evidence on its long-term efficacy and safety in non-diabetic adults with overweight or obesity remains limited. This meta-analysis provides updated evidence by incorporating oral semaglutide data, extended follow-up duration, and comprehensive subgroup analyses. METHODS: We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov databases from inception to April 30, 2024. Randomized controlled trials comparing semaglutide with placebo in non-diabetic adults with BMI ≥27 kg/m2 were included in this study. The Cochrane Risk of Bias 2 tool was used for quality assessment. Data were analyzed using RevMan v5.4. Sensitivity analyses were used to explore the sources of heterogeneity. RESULTS: Seven RCTs involving 5411 participants were included in this review. Semaglutide significantly reduced absolute weight (WMD -12.24 kg, 95 % CI -13.25 to -11.22), percentage weight change (WMD -12.15 %, 95 % CI -13.63 to -10.67), BMI (WMD -4.32 kg/m2, 95 % CI -4.75 to -3.89), and waist circumference (WMD -9.32 cm, 95 % CI -9.87 to -8.78). Semaglutide increased likelihood of achieving ≥5 % weight loss (RR 2.63, 95 % CI 2.12-3.25). Total adverse events were modestly but significantly elevated (RR 1.05, 95 % CI 1.01-1.09), primarily gastrointestinal symptoms. Serious adverse reactions were also higher (RR 1.33, 95 % CI 1.08-1.63). CONCLUSIONS: Both oral and subcutaneous semaglutide significantly improve weight management in non-diabetic adults. While the safety profile is generally acceptable, elevated serious adverse events warrant careful patient selection and monitoring. Optimal outcomes occur with lifestyle interventions at doses ≥2.4 mg weekly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China.
- Department of Orthopedics, 83rd Army Group Hospital, Xinxiang, Henan, China.
- Department of Biostatistics, School of Public Health (Guangdong Provincial Key Laboratory of Tropical Disease Research), Southern Medical University, China.
- Hygienic Company, No. 71282 Troop of PLA, China.
- Department of Biomedical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China. Electronic address: xq.lao@cityu.edu.hk.
Zitieren
APA
Zhang, S., Niu, S., An, S., Cai, X., & Lao, X. (2026). Efficacy and safety of semaglutide in non-diabetic adults with overweight or obesity: A meta-analysis of randomized controlled trials. European Journal of Pharmacology, 1015, 178587. https://doi.org/10.1016/j.ejphar.2026.178587
Vancouver
Zhang S, Niu S, An S, Cai X, Lao X. Efficacy and safety of semaglutide in non-diabetic adults with overweight or obesity: A meta-analysis of randomized controlled trials. European Journal of Pharmacology. 2026;1015:178587. doi:10.1016/j.ejphar.2026.178587
BibTeX
@article{Zhang2026,
author = {Zhang, Shenyue and Niu, Shengbo and An, Shengli and Cai, Xinghai and Lao, Xiangqian},
title = {Efficacy and safety of semaglutide in non-diabetic adults with overweight or obesity: A meta-analysis of randomized controlled trials},
journal = {European Journal of Pharmacology},
year = {2026},
volume = {1015},
pages = {178587},
doi = {10.1016/j.ejphar.2026.178587}
}
EUVIMED